TY - JOUR
T1 - Access to medications among adults with type 2 diabetes using pharmacy- or clinic-based medication assistance programs
T2 - A systematic review
AU - Ward, Lori M.
AU - Pendergrass, Desiree B.
AU - Chima, Charles C.
AU - Thorpe, Roland J.
AU - Bruce, Marino A.
AU - Blackburn, Hillary F.
AU - Palombo, Christopher F.
AU - Beech, Bettina M.
N1 - Publisher Copyright:
© 2020 American Pharmacists Association®
PY - 2020/11/1
Y1 - 2020/11/1
N2 - Objective: The purpose of this systematic review was to assess the literature regarding access to, and utilization of medication for type 2 diabetes (T2D) and pre-post improvements in diabetes outcomes for adults enrolled in clinic- or pharmacy-based medication assistance programs. Data sources: The databases searched were PubMed, CINAHL, Scopus, Embase, Ovid HealthSTAR, PapersFirst, and OpenGrey. Study Selection: Databases were searched from the beginning of each database to Feburary 29, 2020. Articles were included if (1) the population of interest was adults 18 years of age or older with a T2D diagnosis, (2) the study addressed access to medication for diabetes patients in a clinic- or pharmacy-based setting, and (3) the study was conducted in the United States. Data extraction: Data extracted from the selected studies included location of study, patient inclusion criteria, sample size, medication assistance program description, and reported diabetes medication access and medication related adherence outcomes. Results: Eleven articles met the inclusion criteria for the study. The mean reduction in glycated hemoglobin level following the use of medication assistance programs ranged from 0.45 to 0.8. Across studies, the mean number of antihyperglycemic medications used by patients in medication assistance programs ranged from 1 to 1.9. Medication adherence was reported at 45% across studies that reported adherence measures. Conclusion: Among the 11 studies identified that assessed access to medication for adults with T2D using clinic- or pharmacy-based medication assistance programs, study findings indicated that many of these programs showed some positive changes in medication access and diabetes-related outcomes.
AB - Objective: The purpose of this systematic review was to assess the literature regarding access to, and utilization of medication for type 2 diabetes (T2D) and pre-post improvements in diabetes outcomes for adults enrolled in clinic- or pharmacy-based medication assistance programs. Data sources: The databases searched were PubMed, CINAHL, Scopus, Embase, Ovid HealthSTAR, PapersFirst, and OpenGrey. Study Selection: Databases were searched from the beginning of each database to Feburary 29, 2020. Articles were included if (1) the population of interest was adults 18 years of age or older with a T2D diagnosis, (2) the study addressed access to medication for diabetes patients in a clinic- or pharmacy-based setting, and (3) the study was conducted in the United States. Data extraction: Data extracted from the selected studies included location of study, patient inclusion criteria, sample size, medication assistance program description, and reported diabetes medication access and medication related adherence outcomes. Results: Eleven articles met the inclusion criteria for the study. The mean reduction in glycated hemoglobin level following the use of medication assistance programs ranged from 0.45 to 0.8. Across studies, the mean number of antihyperglycemic medications used by patients in medication assistance programs ranged from 1 to 1.9. Medication adherence was reported at 45% across studies that reported adherence measures. Conclusion: Among the 11 studies identified that assessed access to medication for adults with T2D using clinic- or pharmacy-based medication assistance programs, study findings indicated that many of these programs showed some positive changes in medication access and diabetes-related outcomes.
UR - http://www.scopus.com/inward/record.url?scp=85089184418&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089184418&partnerID=8YFLogxK
U2 - 10.1016/j.japh.2020.07.001
DO - 10.1016/j.japh.2020.07.001
M3 - Review article
C2 - 32778516
AN - SCOPUS:85089184418
SN - 1544-3191
VL - 60
SP - e411-e421
JO - Journal of the American Pharmacists Association
JF - Journal of the American Pharmacists Association
IS - 6
ER -